Moving Towards Accountability for Reasonableness – A Systematic Exploration of the Features of Legitimate Healthcare Coverage Decision-Making Processes Using Rare Diseases and Regenerative Therapies as a Case Study

Publish Year: 1398
نوع سند: مقاله ژورنالی
زبان: English
View: 39

This Paper With 20 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_HPM-8-7_005

تاریخ نمایه سازی: 18 مرداد 1403

Abstract:

Background The accountability for reasonableness (A۴R) framework defines ۴ conditions for legitimate healthcare coverage decision processes: Relevance, Publicity, Appeals, and Enforcement. The aim of this study was to reflect on how the diverse features of decision-making processes can be aligned with A۴R conditions to guide decision-making towards legitimacy. Rare disease and regenerative therapies (RDRTs) pose special decision-making challenges and offer therefore a useful case study.   Methods Features operationalizing each A۴R condition as well as three different approaches to address these features (cost-per-QALY-focused and multicriteria-based) were defined and organized into a matrix. Seven experts explored these features during a panel run under the Chatham House Rule and provided general and RDRT-specific recommendations. Responses were analyzed to identify converging and diverging recommendations.   Results Regarding Relevance, recommendations included supporting deliberation, stakeholder participation and grounding coverage decision criteria in normative and societal objectives. Thirteen of ۱۷ proposed decision criteria were recommended by a majority of panelists. The usefulness of universal cost-effectiveness thresholds to inform allocative efficiency was challenged, particularly in the RDRT context. RDRTs raise specific issues that need to be considered; however, rarity should be viewed in relation to other aspects, such as disease severity and budget impact. Regarding Publicity, panelists recommended transparency about the values underlying a decision and value judgements used in selecting evidence. For Appeals, recommendations included a life-cycle approach with clear provisions for re-evaluations. For Enforcement, external quality reviews of decisions were recommended.   Conclusions Moving coverage decision-making processes towards enhanced legitimacy in general and in the RDRT context involves designing and refining approaches to support participation and deliberation, enhancing transparency, and allowing explicit consideration of multiple decision criteria that reflect normative and societal objectives.

Authors

Monika Wagner

Analytica Laser, Montreal, QC, Canada

Dima Samaha

Analytica Laser, London, UK

Roman Casciano

Analytica Laser, New York City, NY, USA

Matthew Brougham

Analytica Laser, Montreal, QC, Canada

Payam Abrishami

National Health Care Institute (ZIN), Diemen, The Netherlands

Charles Petrie

Pfizer Inc, New York City, NY, USA (retired)

Bernard Avouac

Liège University, Liège, Belgium

Lorenzo Mantovani

Center for Public Health Research, University of Milan-Bicocca, Milan, Italy

Antonio Sarría-Santamera

National School of Public Health IMIENS-UNED, Madrid, Spain

Paul Kind

University of Leeds, Leeds, UK

Michael Schlander

Division of Health Economics, German Cancer Research Center (DKFZ), Heidelberg, Germany

Michele Tringali

ASST Niguarda and Regione Lombardia, Welfare Directorate, Milano, Italy

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Definition of legitimacy in English by Oxford Dictionaries. English Oxford ...
  • Terwindt F, Rajan D, Soucat A. Priority-setting for national health ...
  • Clark S, Weale A. Social values in health priority setting: ...
  • Daniels N. Justice, health, and healthcare. Am J Bioeth. ۲۰۰۱;۱(۲):۲-۱۶. ...
  • Goetghebeur M, Castro-Jaramillo H, Baltussen R, Daniels N. The art ...
  • Daniels N. Decisions about access to health care and accountability ...
  • Daniels N. Accountability for reasonableness. BMJ. ۲۰۰۰;۳۲۱(۷۲۷۲):۱۳۰۰-۱۳۰۱ ...
  • Daniels N, van der Wilt GJ. Health technology assessment, deliberative ...
  • Daniels N, Sabin J. Limits to health care: fair procedures, ...
  • Hasman A, Holm S. Accountability for reasonableness: opening the black ...
  • Badano G. If You're a Rawlsian, How Come You're So ...
  • Friedman A. Beyond accountability for reasonableness. Bioethics. ۲۰۰۸;۲۲(۲):۱۰۱-۱۱۲. doi:۱۰.۱۱۱۱/j.۱۴۶۷-۸۵۱۹.۲۰۰۷.۰۰۶۰۵. ...
  • Daniels N, Porteny T, Urritia J. Expanded HTA: enhancing fairness ...
  • Baltussen R, Jansen MPM, Bijlmakers L, et al. Value assessment ...
  • Culyer AJ. Ethics, priorities and cancer. J Cancer Policy. ۲۰۱۷;۱۱:۶-۱۱. ...
  • National Institute for Health and Care Excellence. NICE Process [PMG۹]. ...
  • Gold MR, Stevenson D, Fryback DG. HALYS and QALYS and ...
  • Angelis A, Kanavos P. Multiple Criteria Decision Analysis (MCDA) for ...
  • Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, ...
  • Radaelli G, Lettieri E, Masella C, Merlino L, Strada A, ...
  • Youngkong S, Baltussen R, Tantivess S, Mohara A, Teerawattananon Y. ...
  • Regier DA, Peacock S. Theoretical foundations of MCDA. In: Marsh ...
  • Paulden M, Stafinski T, Menon D, McCabe C. Value-based reimbursement ...
  • Phelps CE, Madhavan G. Using multicriteria approaches to assess the ...
  • Wagner M, Khoury H, Willet J, Rindress D, Goetghebeur M. ...
  • Mitton CR, McMahon M, Morgan S, Gibson J. Centralized drug ...
  • Jansson S. Implementing accountability for reasonablenessthe case of pharmaceutical reimbursement ...
  • Schlander M. NICE accountability for reasonableness: a qualitative study of ...
  • Schlander M. The use of cost-effectiveness by the National Institute ...
  • Greenberg D, Siebzehner MI, Pliskin JS. The process of updating ...
  • Goetghebeur M, Wagner M. Identifying value (s): a reflection on ...
  • Berwick DM, Nolan TW, Whittington J. The triple aim: care, ...
  • Drummond M, Towse A. Orphan drugs policies: a suitable case ...
  • Gericke CA, Riesberg A, Busse R. Ethical issues in funding ...
  • Mahalatchimy A. Reimbursement of cell-based regenerative therapy in the UK ...
  • Corbett MS, Webster A, Hawkins R, Woolacott N. Innovative regenerative ...
  • Nicod E. Why do health technology assessment coverage recommendations for ...
  • Daniels N, Sabin EJ. Setting limits fairly: Learning to Share ...
  • Sandman L, Gustavsson E. Beyond the Black Box Approach to ...
  • Abrishami P, Oortwijn W, Hofmann B. Ethics in HTA: Examining ...
  • Culyer AJ. HTA - Algorithm or Process? Comment on "Expanded ...
  • Oortwijn W, Determann D, Schiffers K, Tan SS, van der ...
  • European Commission. Process on Corporate Social Responsibility in the Field ...
  • Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for ...
  • Iskrov G, Miteva-Katrandzhieva T, Stefanov R. Multi-criteria decision analysis for ...
  • Kolasa K, Zwolinski KM, Kalo Z, Hermanowski T. Potential impact ...
  • Sussex J, Rollet P, Garau M, Schmitt C, Kent A, ...
  • Schlander M, Garattini S, Holm S, et al. Incremental cost ...
  • Nord E. Beyond QALYs: Multi-criteria based estimation of maximum willingness ...
  • National Institute for Health and Care Excellence (NICE). Interim process ...
  • National Institute for Health and Care Excellence (NICE). NICE and ...
  • Scottish Medicines Consortium (SMC). SMC modifiers used in appraising new ...
  • Scottish Medicines Consortium (SMC). PACE (Patient & Clinician Engagement) overview ...
  • Hettle R, Corbett M, Hinde S, et al. The assessment ...
  • Thokala P, Devlin N, Marsh K, et al. Multiple criteria ...
  • Marsh K, M IJ, Thokala P, et al. Multiple criteria ...
  • Frenk J. The global health system: strengthening national health systems ...
  • Ronfard V, Vertes AA, May MH, Dupraz A, van Dyke ...
  • Buckland KF, Bobby Gaspar H. Gene and cell therapy for ...
  • Royal Institute of International Affairs. Chatham House Rule. Royal Institute ...
  • Schlander M, Telser H, Holm S, Marshall D, Nord E, ...
  • Tanios N, Wagner M, Tony M, et al. Which criteria ...
  • Lakdawalla DN, Doshi JA, Garrison LP Jr, Phelps CE, Basu ...
  • Annemans L, Ayme S, Le Cam Y, et al. Recommendations ...
  • EURORDIS. Breaking the access deadlock to leave no one behind. ...
  • Nicod E, Kanavos P. Scientific and social value judgments for ...
  • Silva EN, Sousa TR. Economic evaluation in the context of ...
  • Bertram MY, Lauer JA, De Joncheere K, et al. Cost-effectiveness ...
  • Birch S, Gafni A. The biggest bang for the buck ...
  • Schlander M, Dintsios CM, Gandjour A. Budgetary impact and cost ...
  • Schuller Y, Hollak CE, Biegstraaten M. The quality of economic ...
  • Drummond M, Knies S, Garau M. Sustainable funding and fair ...
  • Linley WG, Hughes DA. Societal views on NICE, cancer drugs ...
  • Wiss J, Levin LA, Andersson D, Tinghog G. Prioritizing rare ...
  • Desser AS, Gyrd-Hansen D, Olsen JA, Grepperud S, Kristiansen IS. ...
  • Dragojlovic N, Rizzardo S, Bansback N, Mitton C, Marra CA, ...
  • Mentzakis E, Stefanowska P, Hurley J. A discrete choice experiment ...
  • Desser AS. Prioritizing treatment of rare diseases: a survey of ...
  • EURORDIS. Rare diseases: Understanding this public health priority. EURORDIS website. ...
  • Abelson J, Wagner F, DeJean D, et al. Public and ...
  • Gagnon MP, Desmartis M, Lepage-Savary D, et al. Introducing patients' ...
  • Rowe G, Frewer LJ. A typology of public engagement mechanisms. ...
  • Douglas CM, Wilcox E, Burgess M, Lynd LD. Why orphan ...
  • Facey K, Granados A, Guyatt G, et al. Generating health ...
  • Menon D, Stafinski T, Dunn A, Wong-Rieger D. Developing a ...
  • Youngkong S, Teerawattananon Y, Tantivess S, Baltussen R. Multi-criteria decision ...
  • Goetghebeur MM, Wagner M, Khoury H, Rindress D, Gregoire JP, ...
  • Wagner M, Khoury H, Bennetts L, et al. Appraising the ...
  • Christiaens W, Kohn L, Leonard C, Denis A, Daue F, ...
  • Abrishami Shirazi P, Boer A, Horstman K. Value in co-creation: ...
  • Hofmann B, Cleemput I, Bond K, et al. Revealing and ...
  • نمایش کامل مراجع